Stock Alert: ERYTECH Pharma Shares Hit 52-Week High

(RTTNews) - Shares of ERYTECH Pharma S.A. (ERYP) touched a 52-week high of $9.77 on April 28, and closed Tuesday's regular trade at $8.29, up 79 cents or 10.53%. ERYP, further, gained $1.46 or 17.61% in the extended trading session.

The company announced that the U.S. FDA has granted eryaspase Fast Track Designation for the development of a second-line treatment of patients with metastatic pancreatic cancer.

ERYTECH's lead product candidate, eryaspase, is being evaluated in a Phase 3 trial (TRYbeCA-1) in second-line metastatic pancreatic cancer in 11 countries in Europe and the United States. More than 75% of the approximately 500 patients to be enrolled in the trial have been randomized.

An interim superiority analysis, to be conducted by an independent data monitoring committee (IDMC) when two-thirds of the events have occurred, is currently expected to take place around year-end 2020 and the final analysis in the second half of 2021.

"This is yet another significant milestone and meaningful validation of our technology as we continue our TRYbeCA-1 Phase 3 trial evaluating eryaspase in second-line metastatic pancreatic cancer," said Gil Beyen, CEO of ERYTECH.